| Name | Minocycline hydrochloride |
| Description | Minocycline hydrochloride (Minocycline HCl) is a tetracycline antibiotic with excellent absorption and tissue penetration that is used for several bacterial infections as well as treatment of acne. Minocycline hydrochloride can cause both an acute hepatitis-like syndrome occurring within 1 to 3 months of starting therapy or a more insidious chronic hepatitis with autoimmune features typically after long-term treatment. |
| In vitro | Minocycline exhibits significant neuroprotective effects in models of cerebral ischemia, traumatic brain injury, Huntington's disease, and Parkinson's disease. Its neuroprotective properties may involve the inhibition of 5-lipoxygenase (an inflammatory enzyme associated with brain aging). Additionally, Minocycline's activity is linked to the inhibition of protein synthesis. |
| In vivo | Minocycline inhibits the release of cytochrome c mediated by the permeability transition in mitochondria. This inhibition by minocycline on cytochrome c release has been demonstrated in vivo, in cells, and isolated mitochondria. Additionally, minocycline suppresses the activity of inducible caspase-1 and caspase-3, inducible nitric oxide synthase (iNOS), and p38 mitogen-activated protein kinase (MAPK). Following experimental focal ischemia, minocycline reduces the upregulation of caspase-1 and iNOS, thereby decreasing infarct size. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 12.4 mg/mL (25.1 mM), Sonication is recommended.
DMSO : 257.5 mg/mL (521.32 mM), Sonication is recommended.
|
| Keywords | Ventricular arrhythmia | stroke | Potassium Channel | PI3K/Akt | ovarian cancer | neuroprotective | Myocardial ischemia | Mitochondrial ATP-sensitive potassium | Minocycline hydrochloride | Minocycline Hydrochloride | Minocycline | MDM-2/p53 | L-type Ca2+ channel | KcsA | Inhibitor | inhibit | infection | Hypoxia-inducible factors | HIFs | HIFProlylHydroxylase | HIF-PH | HIF/HIFProlylHydroxylase | HIF/HIF Prolyl-Hydroxylase | HIF/HIF ProlylHydroxylase | HIF Prolyl-Hydroxylase | HIF ProlylHydroxylase | HIF | cerebral ischemia | Calcium Channel | Ca2+ channels | Ca channels | Bacterial | Apoptosis | Antibiotic | acinetobacter |
| Inhibitors Related | Neomycin sulfate | 2,4,6-Tri-tert-butylphenol | Cysteamine hydrochloride | Adipic dihydrazide | Sulfamethoxazole sodium | Terbinafine hydrochloride | Metronidazole | Copper(Ⅱ) Sulfate | Tributyrin | Alginic acid | Dextran sulfate sodium salt (MW 5000) | BES |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | NO PAINS Compound Library | Anti-Bacterial Compound Library | Stem Cell Differentiation Compound Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library |
United States
